Now Reading: Molbio Diagnostics IPO likely to list at 19% premium on Monday
-
01
Molbio Diagnostics IPO likely to list at 19% premium on Monday
Molbio Diagnostics shares are set to list on the NSE and BSE on Monday, 17 August, with the grey market premium (GMP) of Rs 156 indicating a 19.3% gain over the issue…
The Story in Brief
Molbio Diagnostics shares are set to list on the NSE and BSE on Monday, 17 August, with the grey market premium (GMP) of Rs 156 indicating a 19.3% gain over the issue price of Rs 807. The Rs 940-crore IPO, which included a fresh issue of Rs 200 crore and an offer for sale of 91.66 lakh shares, was subscribed 70 times. The retail portion was booked 13 times and the non-institutional investor segment 50 times.
The company plans to use the fresh issue proceeds to set up a research facility via subsidiary Bigtec, fund capital expenditure for office space, and buy machinery for units in Goa and Visakhapatnam. The book-running lead managers were Kotak Mahindra Capital, IIFL Capital, Jefferies India, and Motilal Oswal. Revenue from operations stood at Rs 1,445.69 crore in FY26, with net profit of Rs 164.14 crore.
The Indian Opinion
The grey market premium for Molbio Diagnostics is being treated as a near-certain indicator of a successful debut. While past IPOs have shown that GMP can be misleading, this IPO's 70-times subscription suggests genuine demand. The real test will be the stock's movement in the first week, when early profit-booking by institutional investors could flatten the pop. Watch how the stock trades on Tuesday instead.
Source: livemint.com
This story was synthesised by AI from the source linked above.
